Study of BT02 for blood cancers that came back or did not respond
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug, BT02, for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have returned or not improved after treatment. The goal is to see if BT02 can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 69 years old.
- You have a blood cancer (leukemia, lymphoma, or multiple myeloma) that has come back or not responded to treatment.
- If you have leukemia, your bone marrow must show at least 5% cancer cells (blasts).
- You are generally active and able to care for yourself (ECOG score 0-1).
- You are expected to live at least 3 more months.
- You agree to use effective birth control during the study if you or your partner can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This trial tests a new drug called BT02 for people with advanced lung cancer that has not responded to previous treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
This trial tests a new drug (BT02) for advanced melanoma that has stopped responding to earlier treatments. The goal is to see if it is safe and may help shrink tumors.
This study tests a new drug called BG-75202, alone or combined with other treatments, for myeloid malignancies (blood cancers affecting bone marrow cells) that have returned or stopped responding to previous treatment. The goal is to see if this drug can help control the cancer.
Hear when a new Relapsed or Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.